Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein.
Okuda
Tomoki
T
Oh-i
Tsunao
T
D000284:Administration, Oral; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016572:Cyclosporine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004357:Drug Synergism; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*
D000924:Anticholesteremic Agents; D003879:Dermatologic Agents; D005229:Fatty Acids, Monounsaturated; D007166:Immunosuppressive Agents; D007211:Indoles; D008077:Lipoproteins, LDL; D000077340:Fluvastatin; D016572:Cyclosporine